FDA Cites Akorn’s Exhibit Banner At ASHP Clinical Conference
This article was originally published in The Pink Sheet Daily
Executive Summary
Booth promotion for Nembutal fails to disclose any risk information, Office of Prescription Drug Promotion says in the fifth letter issued this year.
You may also be interested in...
FDA's Decline In Promotion Enforcement Highlighted By Celator Booth Letter
FDA's Office of Prescription Drug Promotion issues only its third letter of 2016, although it hopes to cast wide net by targeting high-profile events like ASCO.
FDA Turns Off Otsuka’s Abilify Dimmer Switch Graphic
As lights go out on the franchise, FDA says pharmacology aid misleadingly suggests Abilify offers advantages over other treatments.
Arbor Emphasizes Risks Of Its Own Product In Suit Against US FDA To Block Nymalize Generics
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: